Of course, combination comes on top, but if the monotherapy was not competitive, it would be hard to move it into Phase III. The oral GLP-1RA is far from the only obesity drug in AstraZenecas pipeline, said Sharon Barr, executive vice president of BioPharmaceuticals R&D at AstraZeneca
Wolverine Peptide Dosing: What Clinical Protocols Actually Look Like Dosing in clinical settings varies based on injury severity, patient weight, and treatment goals
10.1128/CMR.00338-20 407 SouzaP
SARS-CoV-2 variants pose a general concern for the efficacy of neutralizing antibodies that may fail to neutralize infection, raising the possibility of a more severe form of COVID-19
That means your plan should match what is happening in your body and in your daily routine, not just what sounds minimal on paper